Seizure responses and induction of Fos by the NMDA Agonist (tetrazol-5-yl)glycine in a genetic model of NMDA receptor hypofunction

Brain Research

Volumn 1221, Issue , 2008, Pages 41-48

  Duncan, Gary E ^a   Inada, Ken ^a   Farrington, Joseph S ^a   Koller, Beverly H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Brain stem; Fos; Hippocampus; Hypothalamus; NMDA receptor; Seizure

Indexed keywords

(TETRAZOL 5 YL)GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PROTEIN FOS; RECEPTOR SUBUNIT;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN REGION; BRAIN STEM; CONTROLLED STUDY; FEMALE; GENE INDUCTION; GENOTYPE; HIPPOCAMPUS; HYPOTHALAMUS; HYPOTHALAMUS NUCLEUS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MOUSE STRAIN; MUTANT; NEUROANATOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEIZURE; SOLITARY TRACT NUCLEUS; WILD TYPE;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EXCITATORY AMINO ACID AGONISTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; GLYCINE; HYPOTHALAMUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES; SEPTAL NUCLEI; SOLITARY NUCLEUS; SYNAPTIC TRANSMISSION; TETRAZOLES;

MUS;

EID: 46049094602     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.05.001     Document Type: Article

References (34)

1. Andre V., Pineau N., Motte J.E., Marescaux C., and Nehlig A. Mapping of neuronal networks underlying generalized seizures induced by increasing doses of pentylenetetrazol in the immature and adult rat: a c-Fos immunohistochemical study. Eur. J. Neurosci. 10 (1998) 2094-2106
2. Barton M.E., Klein B.D., Wolf H.H., and Steve W. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47 (2001) 217-227
3. Cohen-Gadol A.A., Brffton J.W., Wetjen N.M., Marsh W.R., Meyer F.B., and Raffel C. Neurostimulation therapy for epilepsy: current modalities and future directions. Mayo Clin. Proc. 78 (2003) 238-248
4. Dingledine R., McBain C.J., and McNamara J.O. Excitatory amino-acid receptors in epilepsy. Trends in Pharmacological Sciences 11 (1990) 334-338
5. Duncan G.E., Johnson K.B., and Breese G.R.T. Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J. Neuroscience 13 (1993) 3932-3943
6. Duncan G.E., Miyamoto S., Gu H.B., Lieberman J.A., Koller B.H., and Snouwaert J.N. Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Res. 951 (2002) 166-176
7. Duncan G.E., Moy S.S., Perez A., Eddy D.M., Zinzow W.M., Lieberman J.A., Snouwaert J.N., and Koller B.H. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav. Brain Res. 153 (2004) 507-519
8. Duncan G.E., Moy S.S., Lieberman J.A., and Koller B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 184 (2006) 190-200
9. Eells J.B., Clough R.W., Browning R.A., and Jobe P.C. Comparative Fos immunoreactivity in the brain after forebrain, brainstem, or combined seizures induced by electroshock, pentylenetetrazol, focally induced and audiogenic seizures in rats. Neuroscience 123 (2004) 279-292
10. Ferland R.J., and Applegate C.D. The role of the ventromedial nucleus of the hypothalamus in epileptogenesis. Neuroreport 9 (1998) 3623-3629
11. Fradley R.L., O'Meara G.F., Newman R.J., Andrieux A., Job D., and Reynolds D.S. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 163 (2005) 257-264
12. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
13. Groves D.A., and Brown V.J. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neurosci. Biobehav. Rev. 29 (2005) 493-500
14. Inada K., Farrington J.S., Moy S.S., Koller B.H., and Duncan G.E. Assessment of NMDA receptor activation in vivo by Fos induction after challenge with the direct NMDA agonist (tetrazol-5-yl)glycine: effects of clozapine and haloperidol. J. Neural Transm. 114 (2007) 899-908
15. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
16. Kanter R.K., Strauss J.A., and Sauro M.D. Comparison of neurons in rat medulla oblongata with Fos immunoreactivity evoked by seizures, chemoreceptor, or baroreceptor stimulation. Neuroscience 73 (1996) 807-816
17. Klitgaard H. Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol. Scand. 112 (2005) 68-72
18. Knapp D.J., Braun C.J., Duncan G.E., Qian Y., Fernandes A., Crews F.T., and Breese G.R. Regional specificity of ethanol and NMDA action in brain revealed with FOS-like immunohistochemistry and differential routes of drug administration. Alcohol.: Clin. Exp. Res. 25 (2001) 1662-1672
19. Konradi C., Leveque J.C., and Hyman S.E. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J. Neurosci. 16 (1996) 4231-4239
20. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 (1994) 199-214
21. Lahti A.C., Koffel B., LaPorte D., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 (1995) 9-19
22. Lahti A.C., Weiler M.A., Tamara M.B., Parwani A., and Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25 (2001) 455-467
23. Lunn W.H.W., Schoepp D.D., Calligaro D.O., Vasileff R.T., Heinz L.J., Salhoff C.R., and Omalley P.J. Dl-tetrazol-5-ylglycine, a highly potent NMDA agonist - its synthesis and NMDA receptor efficacy. J. Med. Chem. 35 (1992) 4608-4612
24. Miyamoto S., Snouwaert J.N., Koller B.H., Moy S.S., Lieberman J.A., and Duncan G.E. Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction. Neuropsychopharmacology 29 (2004) 2180-2188
25. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
26. Moy S.S., Perez A., Koller B.H., and Duncan G.E. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. Brain Res. 1089 (2006) 186-194
27. Nemeroff C.B., Mayberg H.S., Krahl S.E., McNamara J., Frazer A., Henry T.R., George M.S., Charney D.S., and Brannan S.K. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 31 (2006) 1345-1355
28. Ohno M., Yoshida H., and Watanabe S. Nmda receptor-mediated expression of Fos protein in the rat striatum following methamphetamine administration - relation to behavioral sensitization. Brain Res. 665 (1994) 135-140
29. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 (1995) 998-1007
30. Schoepp D.D., Smith C.L., Lodge D., Millar J.D., Leander J.D., Sacaan A.I., and Lunn W.H.W. d,l-(tetrazol-5-yl) glycine - a novel and highly potent NMDA receptor agonist. Eur. J. Pharmacol. 203 (1991) 237-243
31. Snyderkeller A.M. Striatal c-Fos induction by drugs and stress in neonatally dopamine-depleted rats given nigral transplants - importance of NMDA activation and relevance to sensitization phenomena. Exp. Neurol. 113 (1991) 155-165
32. Velisek L., Jehle K., Asche S., and Veliskova J. Model of infantile spasms induced by N-methyl-d-aspartic acid in prenatally impaired brain. Ann. Neurol. 61 (2007) 109-119
33. Vollenweider F.X., Leenders K.L., Oye I., Hell D., and Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur. Neuropsychopharmacol. 7 (1997) 25-38
34. Vonck K., Thadani V.Y., Gilbert K., Dedeurwaerdere S., De Groote L., De Herdt V., Goossens L., Gossiaux F., Achten E., Thiery E., Vingerhoets G., Van Roost D., Caemaert J., De Reuck J., Roberts D., Williamson P., and Boon P. Vagus nerve stimulation for refractory epilepsy: a transatlantic experience. J. Clin. Neurophysiol. 21 (2004) 283-289